OncoDNA’s Post

After a few challenging years, 2024 has been exceptional for us. We achieved broad adoption of our first tumor profiling kit, Comprehensive Genomic Profiling OncoDEEP, and regained the growth that placed us among Deloitte's FAST50 winners in 2018 and 2020. Looking ahead, 2025 promises to be even more exciting with the launch of our second liquid biopsy kit OncoSELECT and innovations in minimal residual disease (MRD) detection. MRD is a hot topic for adoption in 2025, particularly in clinical and pharmaceutical research, as it enables earlier intervention and more precise treatment strategies. Stay tuned for more information coming very soon! #InnovationInOncology #LiquidBiopsy #MRD #CancerResearch #OncoDEEP #FAST50 #PrecisionMedicine

Much of the burden experienced in clinical research comes down to fragmented communication across systems and teams. Vinh La, Clinical Operations Lead involved in a multi-cohort, Global Phase II Oncology study, turned to Advarra Longboat to centralize critical communication and documents. Longboat helps streamline key workflows and improve collaboration between its 180,000 users every day. See how you can cut down on fragmented communication and improve compliance today by clicking the link in our comments below. ⬇️ #ClinicalResearch #ClinicalTrials

Speaking at our 11th Annual Clinical Trials in Oncology conference in Munich, Suvoda’s Senior Solutions Consultant Daniela Duffett detailed how long and burdensome processes can cost patients, time and data. Click here for the full article - https://lnkd.in/dV7-DQsY #clinicaltrials #clinicaldata

Are you attending ESMO Congress 2024? Schedule a meeting with UBC’s evidence development experts and learn how we can help modernize your oncology study design and execution at any stage of the clinical development lifecycle https://hubs.li/Q02Pd2MM0 #PatientsFirst #ESMO2024 #ClinicalTrials #EvidenceGeneration #DrugSafety

Are you attending #ASCO24? Hear from our EVP, Medical Strategy, Matthew Hoelzle, and our SVP, Medical Strategy, Patty Zipfel, PhD, as they share what they are most looking forward to in the video below. #Oncology #ReimagineHealth #BioPharma #Healthcare #InizioEvoke

At Ergomed, patient-centricity is not just a buzzword, it's our guiding principle. In this white paper, ERGOMED delves into improved patient-reported outcome (PRO) tools and data to measure patients' quality of life during oncology clinical trials. We believe that by truly understanding and addressing patients and their care partners' needs, we can contribute to developing therapies that make a real difference in patients' lives. We work closely with study sponsors to connect with patients and their advocates and to educate patients and care partners about the clinical trial experience. Gain insight on how Ergomed is continuing to make a difference: https://lnkd.in/gTgMAVeW #Ergomed #Patientcentricity #ClinicalResearchServices #OncologyCRO

Join our Omega Education Team for the Tumor Talk webinar on Wednesday, November 20th, 2024, 12-1 EDT, titled ‘Tumor Talk: Interpreting Complex AJCC Concepts.’ Our Oncology Data expert, Janet Vogel, will dive into advanced AJCC staging concepts and guide you through assigning stages in complex scenarios. Don’t miss this valuable session to enhance your knowledge! Register Now. https://bit.ly/3CjGVVr #TumorTalk #OncologyData #AJCC #HealthcareEducation #Healthcare #Webinar #HealthcareWebinar

Thank you for meeting with us at PMLS Precision Oncology & Diagnostics 2024 in Chicago! Our Chief Precision Medicine Officer, Susanne Munksted, delivered a talk on “Are We Closer to Fulfilling the Patient Promise of Precision Oncology?” This presentation expanded on insights from Diaceutics’ globally recognized Practice Gaps report, providing an update on how these practice gaps have evolved since 2022. Susanne also highlighted actionable steps the industry can take to address operational, economic, and policy challenges in precision medicine, drawing from the five key recommendations outlined by The Health and Economic Forum in the newly released Recommendations paper. For more information, and to download the recommendations paper, click the link below: https://lnkd.in/e7FnGF49 #PrecisionMedicine #BetterTestingBetterTreatement

Roche is reportedly exploring options for its Flatiron Health unit, a leader in #cancer data specialization. All options are on the table, including #divesting the business or finding a strategic #partner to co-manage operations. In 2018, Roche made waves by #acquiring Flatiron Health for a staggering $1.9 billion. The company aimed to leverage Flatiron’s real-world evidence databank to enhance #personalized healthcare strategies in #oncology. This move was hailed as one of the boldest in the industry, underlining Roche's commitment to innovation in #cancer treatment. However, the landscape has shifted significantly. Many of the Roche executives who championed the Flatiron #acquisition have since moved on, and the company has faced challenges reflected in its two-year period of share price decline. Stay informed. Stay ahead. Together, let's shape the future of healthcare. 🌟 https://lnkd.in/dxg7bkka

Advancing a Complex Clinical Trial Ahead of Schedule! 📢 ERGOMED is proud to announce that our client's complex clinical trial has advanced ahead of schedule! Navigating a complex and challenging study protocol with stringent timelines requires a structured, high-quality, flexible, and proactive approach. Our collaboration with the sponsor during the early planning stages and the unified efforts of our feasibility, start-up, regulatory, medical, site management, and operational teams were critical to the study's success. 🚀   Read the Case Study: https://lnkd.in/e69p9vh6   #ClinicalResearch #ComplexClinicalTrials #Oncology #SuccessStory